Últimas noticias sobre Molina Healthcare (NYSE:MOH) Bolsa

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

News

Global

Markets

ACIC

BABA

BIDU

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

Trading Ideas

OLPX

Scion Asset Management 13F Shows Increased Stake In Alibaba Group From 155,000 To 200,000 Shares; Increased Stake In JD.com From 250,000 To 500,000 Shares;  Increased Stake In Shift4 Payments From 100,000 To 150,000 Shares; Increased Stake In Baidu From 75,000 To 125,000 Shares; Increased Stake In Molina Healthcare From 24,530 To 30,000 Shares; Increased Stake In Olaplex Holdings From 995,250 To 1,000,000 Shares

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $360 to $362.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $362

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.8% on an annualized basis producing an average annual return of 13.16%. Currently, Molina Healthcare has a market capitalization of $18.13 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,261.31 today based on a price of $317.01 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730136615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Molina Healthcare 20 Years Ago Would Be Worth This Much Today

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares jumped 21.97% following the earnings<a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener"> beat and overall market strength</a>.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares increased 14.02% last week. The People's Bank of China <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">injected 700 billion yuan</a> ($98.36 billion) into the banking system through its one-year medium-term lending facility, keeping the rate steady at 2.0%.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock surged 12.36% after the company<a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener"> reported third-quarter results</a>.</li>
<li>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) shares gained 11.83% following a report alleging that a <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">judge blocked the company's proposed acquisition</a> of Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>). The company said it intends to appeal the decision.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 11.30% last week after several analysts <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">raised their price forecasts</a> on the stock.</li>
<li>Booz Allen Hamilton Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares gained 10.99% after reporting better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">strong FY25 guidance</a>.</li>
<li>Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) shares upped 9.45% after reporting better-than-expected Q3 FFO results and raising FY24 FFO guidance. Several analysts <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">raised their price forecasts</a> on the stock.</li>
<li>Grab Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) stock gained 9.12% last week. Daiwa Capital initiated coverage on the stock with an Outperform rating and <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">a $4.60 price target</a>.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares were up <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% amid a rise in Bitcoin</a>.</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) shares upped 8.03% after the company reported better-than-expected third-quarter results and several <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">analysts raised the price target</a>.</li>
</ol>
Photo via Shutterstock

Large Cap

Movers

CPRI

GRAB

MSTR

TSLA

Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $359 to $372.

Barclays Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $372

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded down 0.42% to 42,337.45 while the NASDAQ rose 0.65% to 18,396.30. The S&amp;P 500 also rose, gaining, 0.15% to 5,806.21.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 3.2% on Thursday.
In trading on Thursday, materials shares fell by 1.4%.
Top Headline
Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) reported better-than-expected third-quarter results.
Sales rose 1% year over year to $10.88 billion, beating the consensus of $10.65 billion, on higher sales in the U.S. and Canada. Adjusted EPS was $0.47, beating the consensus of $0.46.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 116% to $0.5406. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 24% to $6.43 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 20% to $330.40 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 33% to $6.39 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 82% to $0.3019 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.29 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $70.08 while gold traded up 0.7% at $2,748.60.
Silver traded down 0.1% to $33.825 on Thursday, while copper rose 0.6% to $4.3605.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.03%, Germany's DAX gained 0.34% and France's CAC 40 rose 0.08%. Spain's IBEX 35 Index fell 0.21%, while London's FTSE 100 rose 0.13%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

BYON

MRNS

Crude Oil Down 1%; Dow Posts Upbeat Earnings

Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight and maintains $406 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Molina Healthcare, Maintains $406 Price Target

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.3% on Thursday.
The Dow traded down 0.72% to 42,206.88 while the NASDAQ rose 0.26% to 18,323.75. The S&amp;P 500 also fell, dropping, 0.16% to 5,788.23.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.6% on Thursday.
In trading on Thursday, materials shares fell by 1.1%.
Top Headline
Shares of Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) fell around 4% on Thursday after the company reported third-quarter results and updated FY24 guidance.
Revenue grew 6% year-over-year (organic: +3%) to $9.728 billion, missing the consensus of $9.901 billion. Adjusted EPS was $2.58 (+8% Y/Y), beating the consensus of $2.50.
For FY24, the company lowered sales guidance to $38.6 billion – $38.8 billion (from $39.1 billion – $39.7 billion prior) versus the consensus of $39.20 billion. Honeywell tightened adjusted EPS guidance to $10.15 – $10.25 (from $10.05 – $10.25) versus the estimate of $10.13.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 216% to $0.7930. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 25% to $6.49 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 22% to $336.39 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 26% to $7.03 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 80% to $0.3413 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.2550 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.29 while gold traded up 0.4% at $2,741.10.
Silver traded down 0.1% to $33.790 on Thursday, while copper fell 0.1% to $4.3350.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.25%, Germany's DAX gained 0.54% and France's CAC 40 rose 0.27%. Spain's IBEX 35 Index rose 0.12%, while London's FTSE 100 rose 0.28%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Earnings

Eurozone

Commodities

Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ASTS

CBRE

PEGA

PLXS

POOL

RKLB

TMUS

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $377.14, a high estimate of $406.00, and a low estimate of $331.00. Observing a downward trend, the current average is 0.11% lower than the prior average price target of $377.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1729771211_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Molina Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$331.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$360.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$353.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$378.00</td>
<td>$351.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molina Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Molina Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Molina Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>About Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 18.65%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.05%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 6.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Molina Healthcare: Insights From 7 Financial Analysts

WIIM

Molina Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results.

Baird analyst Michael Ha maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Outperform and lowers the price target from $405 to $331.

Baird Maintains Outperform on Molina Healthcare, Lowers Price Target to $331

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 16.2% to $0.16 during Wednesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 9.85% to $0.75. The market value of their outstanding shares is at $71.8 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock rose 9.45% to $301.0. The company's market cap stands at $17.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 8.94% to $2.8. The market value of their outstanding shares is at $22.3 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) shares increased by 7.63% to $1.15. The market value of their outstanding shares is at $102.1 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 7.36% to $0.36. The company's market cap stands at $3.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares decreased by 10.9% to $0.49 during Wednesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock decreased by 8.17% to $3.26. The market value of their outstanding shares is at $1.1 billion. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 6.9% to $1.35. The market value of their outstanding shares is at $18.2 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares declined by 6.67% to $5.18. The market value of their outstanding shares is at $719.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 6.48% to $0.28. The market value of their outstanding shares is at $10.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 6.39% to $0.3. The company's market cap stands at $22.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BIAF

BIVI

CNSP

DBVT

ENVB

INAB

MBIO

PTPI

12 Health Care Stocks Moving In Wednesday's After-Market Session

2024 Guidance
Premium revenue for the full year is unchanged and expected to be approximately $38 billion, an increase of approximately 17% from the full year 2023.
Adjusted earnings per diluted share for the full year is unchanged and expected to be at least $23.50, representing approximately 13% growth over the full year 2023. Continued strong performance due to Marketplace, operating leverage, and higher net investment income are expected to offset the higher-than-expected trend in Medicaid and Medicare in the second half of the year.

Guidance

Molina Healthcare Reaffirms FY24 Guidance With Expected Premium Revenue Of ~$38B Vs $39.79B Est.; Adjusted Earnings Of At Least $23.50 Vs $23.51 Est.

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) reported quarterly earnings of $6.01 per share which beat the analyst consensus estimate of $5.94 by 1.18 percent. This is a 19.01 percent increase over earnings of $5.05 per share from the same period last year. The company reported quarterly sales of $10.34 billion which beat the analyst consensus estimate of $9.92 billion by 4.23 percent. This is a 20.96 percent increase over sales of $8.55 billion the same period last year.

Earnings Beats

Molina Healthcare Q3 EPS $6.01 Beats $5.94 Estimate, Sales $10.34B Beat $9.92B Estimate

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) will release its quarterly earnings report on Wednesday, 2024-10-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Molina Healthcare to report an earnings per share (EPS) of $5.96.
Investors in Molina Healthcare are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.31 in the last quarter, leading to a 12.28% increase in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2024/1729609317_0_0.png" alt="eps graph" />
<h3>Analysts' Perspectives on Molina Healthcare</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Molina Healthcare.
Analysts have given Molina Healthcare a total of 10 ratings, with the consensus rating being Neutral. The average one-year price target is $368.3, indicating a potential 28.51% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of HealthEquity, Clover Health Investments and Alignment Healthcare, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for HealthEquity, with an average 1-year price target of $102.14, indicating a potential 64.36% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Clover Health Investments, with an average 1-year price target of $4.0, suggesting a potential 98.6% downside.</li>
<li>Alignment Healthcare is maintaining an Buy status according to analysts, with an average 1-year price target of $10.0, indicating a potential 96.51% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for HealthEquity, Clover Health Investments and Alignment Healthcare, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molina Healthcare</td>
<td>Neutral</td>
<td>18.65%</td>
<td>$1.21B</td>
<td>6.45%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>23.15%</td>
<td>$204.05M</td>
<td>1.68%</td>
</tr>
<tr>
<td>Clover Health Investments</td>
<td>Neutral</td>
<td>11.28%</td>
<td>$107.91M</td>
<td>2.40%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>47.34%</td>
<td>$75.97M</td>
<td>-18.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Molina Healthcare ranks in the middle among its peers for revenue growth. It ranks at the bottom for gross profit. It ranks at the top for return on equity.
<h3>Delving into Molina Healthcare's Background</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 18.65%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Molina Healthcare's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.05%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.45% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
<a href="https://www.benzinga.com/quote/MOH/earnings">To track all earnings releases for Molina Healthcare visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Molina Healthcare's Quarterly Earnings

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock lost 16.35% last week as U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">fell after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) stock dipped 15.58%, probably due to continued weakness following weak guidance from ASML.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares were down 14.38%. The company will report <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">third-quarter results on October 25</a>.</li>
<li>Elevance Health shares dipped 14.17% after analysts cut forecasts <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">following third-quarter earnings</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares tumbled 13.97% after the company accidentally released earnings a day ahead of schedule and <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">cut its 2025 sales forecast</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) stock fell 13.91%, as did U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were down 12.24%, probably in sympathy with Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), which reported third-quarter earnings miss and issued soft FY24 guidance.</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock dived 12.12%, probably in sympathy with Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), which reported better-than-expected <a href="https://www.benzinga.com//node/41377745" target="_blank" rel="noreferrer noopener">earnings and issued strong guidance</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) fell 9.92% last week after Spruce Point Management <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">issued a short-sell report</a> on the stock. The company was under pressure due to Category 5 Hurricane Milton.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 9.44% last week after the company <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">cut its Q3 outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Short Sellers

ASML

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?

Health insurers climb after Trump win

Health insurers climb after Trump win (update)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH – Research Report), Avidity...

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)

Trump Win Gives Some U.S. Health Insurers A Post-Election Bump On Wall Street

Mizuho Securities analyst Ann Hynes has reiterated their bullish stance on MOH stock, giving a Buy rating on October 25. Ann Hynes has given her Bu...

Strategic Growth and Resilience Drive Buy Rating for Molina Healthcare

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Molina Healthcare (MOH – Research Report), with a price t...

Molina Healthcare: Hold Rating Amid Growth Challenges and Legislative Risks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Autolus Therapeutics (AUTL – Research Report), Molina Healthcare ...

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)

Analyzing And Valuing Molina Healthcare As A Solid Company

Molina Healthcare ( ($MOH) ) has issued an update. Molina Healthcare, Inc. plans a private offering of $500 million in senior notes due 2033, aimin...

Molina Healthcare Plans $500M Private Offering of Notes

Fidelity Growth Strategies Fund Q3 2024 Review

ANAB

AUTL

DOCS

MLTX

OSCR

PLTR

PODD

Press Releases

Molina Healthcare Awarded New Florida Medicaid Contract

Molina Healthcare to Acquire ConnectiCare

Molina Healthcare Reports Second Quarter 2024 Financial Results

Molina Healthcare Signs CEO Joe Zubretsky to New Employment Agreement

Molina Healthcare Senior Executive Vice President and CFO Mark Keim to Expand Role to Include Leadership of the Medicaid Health Plans and Marketplace Business

Comments

Molina Healthcare

Noticias

Últimas noticias sobre Molina Healthcare (NYSE:MOH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL